Presented by Dr Gertjan Rasschaert (University Hospitals Leuven – Belgium)
Dr Gertjan Rasschaert introduces the AZUR- 4 trial, a randomised, open-label Phase 2 study for high-risk stage 2 or 3 MSS colorectal cancer. This neoadjuvant trial, co-conceptualised by Leuven, compares CAPEOX plus dostarlimab (an anti-PD-1 inhibitor) against CAPEOX alone for 12 weeks before surgery.
The trial, which recently commenced in Belgium with a network of 10 participating centers, emphasises extensive translational research. This includes advanced techniques like single-cell sequencing and spatial transcriptomics at various time points, making it unique among neoadjuvant colorectal cancer trials. AZUR-4 aims to recruit 120-150 patients across Belgium, the UK, Switzerland, and Spain. This innovative Belgian neoadjuvant platform seeks to attract future pharmaceutical trials.
References:
Rasschaert G. et al., ASCO 2025, TPS3649
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in